III期临床试验-话题@MedSci

#III期临床试验#

101篇内容 | 2162人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1588030, encodeId=ec4a1588030b1, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果, objectType=article, longId=166801, objectId=1b1b16680115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b1b16680115, replyNumber=0, likeNumber=90, createdTime=2019-05-27, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b1b16680115, moduleTitle=辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b1b16680115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588029, encodeId=c1fd15880292a, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血, objectType=article, longId=165917, objectId=84ae16591e2f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84ae16591e2f, replyNumber=0, likeNumber=68, createdTime=2019-05-14, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84ae16591e2f, moduleTitle=III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84ae16591e2f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588028, encodeId=97fc158802880, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, objectType=article, longId=165652, objectId=69a116565258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a116565258, replyNumber=0, likeNumber=71, createdTime=2019-05-09, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a116565258, moduleTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69a116565258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588027, encodeId=c6c8158802e1b, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, objectType=article, longId=164909, objectId=f4ff16490983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ff16490983, replyNumber=0, likeNumber=30, createdTime=2019-04-25, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ff16490983, moduleTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ff16490983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588026, encodeId=a76d158802695, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, objectType=article, longId=164340, objectId=bc7c1643405d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7c1643405d, replyNumber=0, likeNumber=33, createdTime=2019-04-17, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7c1643405d, moduleTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7c1643405d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588025, encodeId=6de11588025c6, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册, objectType=article, longId=164219, objectId=e04a16421946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e04a16421946, replyNumber=0, likeNumber=57, createdTime=2019-04-15, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e04a16421946, moduleTitle=Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e04a16421946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588024, encodeId=76d1158802481, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, objectType=article, longId=163509, objectId=ad4a1635092f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad4a1635092f, replyNumber=0, likeNumber=89, createdTime=2019-04-04, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad4a1635092f, moduleTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad4a1635092f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588023, encodeId=cf7f15880234a, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, objectType=article, longId=161504, objectId=8f841615044d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f841615044d, replyNumber=0, likeNumber=43, createdTime=2019-03-03, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f841615044d, moduleTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f841615044d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588022, encodeId=1f331588022f1, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , objectType=article, longId=161247, objectId=7cfc16124ea4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cfc16124ea4, replyNumber=0, likeNumber=32, createdTime=2019-02-28, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cfc16124ea4, moduleTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cfc16124ea4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588021, encodeId=4cdd1588021af, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功, objectType=article, longId=161192, objectId=ee9f16119219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee9f16119219, replyNumber=0, likeNumber=72, createdTime=2019-02-28, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee9f16119219, moduleTitle=双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee9f16119219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588020, encodeId=1f721588020d5, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, objectType=article, longId=160650, objectId=909e1606500c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909e1606500c, replyNumber=0, likeNumber=61, createdTime=2019-02-22, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909e1606500c, moduleTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=909e1606500c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588019, encodeId=311f1588019e4, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, objectType=article, longId=160546, objectId=fa9316054665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9316054665, replyNumber=0, likeNumber=107, createdTime=2019-02-21, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9316054665, moduleTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa9316054665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588018, encodeId=75da1588018ab, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, objectType=article, longId=160438, objectId=5b3116043863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b3116043863, replyNumber=0, likeNumber=121, createdTime=2019-02-20, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b3116043863, moduleTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b3116043863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588017, encodeId=bb26158801e66, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验, objectType=article, longId=160421, objectId=524e160421b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=524e160421b4, replyNumber=0, likeNumber=69, createdTime=2019-02-20, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=524e160421b4, moduleTitle=以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=524e160421b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588016, encodeId=dac915880168d, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, objectType=article, longId=160414, objectId=ea1416041497, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea1416041497, replyNumber=0, likeNumber=38, createdTime=2019-02-20, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea1416041497, moduleTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea1416041497)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588015, encodeId=f63e1588015d2, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始, objectType=article, longId=160342, objectId=a54e16034284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a54e16034284, replyNumber=0, likeNumber=71, createdTime=2019-02-19, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a54e16034284, moduleTitle=治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a54e16034284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588014, encodeId=6f5715880149e, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle=Incyte宣布开展Ruxolitinib的III期临床试验, objectType=article, longId=156672, objectId=aeee1566e228, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeee1566e228, replyNumber=0, likeNumber=61, createdTime=2018-12-27, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeee1566e228, moduleTitle=Incyte宣布开展Ruxolitinib的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeee1566e228)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588013, encodeId=a9031588013e3, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, objectType=article, longId=156456, objectId=54b315645636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54b315645636, replyNumber=0, likeNumber=92, createdTime=2018-12-24, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54b315645636, moduleTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54b315645636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588012, encodeId=131415880128c, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, objectType=article, longId=156414, objectId=bb9a156414cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb9a156414cc, replyNumber=0, likeNumber=48, createdTime=2018-12-24, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb9a156414cc, moduleTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb9a156414cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1588011, encodeId=181815880119f, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, objectTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, objectType=article, longId=156388, objectId=8ee71563888f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ee71563888f, replyNumber=0, likeNumber=138, createdTime=2018-12-23, rootId=0, userName=guihongzh, userId=d24217580122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ee71563888f, moduleTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ee71563888f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期临床试验

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果

2019-05-27

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血

2019-05-14

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点

2019-05-09

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功

2019-04-25

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险

2019-04-17

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册

2019-04-15

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验

2019-04-04

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功

2019-03-03

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 

2019-02-28

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功

2019-02-28

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

默克Keytruda治疗晚期肝癌的III期临床试验失败告终

2019-02-22

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率

2019-02-21

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验

2019-02-20

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验

2019-02-20

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率

2019-02-20

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始

2019-02-19

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

Incyte宣布开展Ruxolitinib的III期临床试验

2018-12-27

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

"PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开

2018-12-24

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

"PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动

2018-12-24

guihongzh (审核中...)

前往app查看评论内容

#III期临床试验#

"PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动

2018-12-23

科室
- - 订阅+
  - 更多科室
工具
服务